Advanced Gastrointestinal Stromal Tumors clinical trials

Explore recruiting advanced gastrointestinal stromal tumors clinical trials.

Recruiting advanced gastrointestinal stromal tumors studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Gastrointestinal Stromal Tumors trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib

Spain, Netherlands, Norway, Italy, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2 Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of the Oral KIT Inhibitor THE-630 in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)

Spain, France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

ATEZOGIST – A prospective, randomized, multicenter, comparative study of the efficacy of imatinib resumption combined with atezolizumab versus imatinib resumption alone in patients with unresectable advanced gastrointestinal stromal tumors (GIST) after failure of standard treatments

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Advanced Gastrointestinal Stromal Tumors trials by city

Advanced Gastrointestinal Stromal Tumors clinical trials

Recruiting advanced gastrointestinal stromal tumors studies right now

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments

Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)

Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

Agnostic Therapy in Rare Solid Tumors

PH 2 Pemigatinib in SDH-deficient GIST

The Efficacy and Safety of Temozolomide in SDH-deficient GIST

Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Also recruiting in Europe

A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib

A Phase 1/2 Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of the Oral KIT Inhibitor THE-630 in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)

ATEZOGIST – A prospective, randomized, multicenter, comparative study of the efficacy of imatinib resumption combined with atezolizumab versus imatinib resumption alone in patients with unresectable advanced gastrointestinal stromal tumors (GIST) after failure of standard treatments

Advanced Gastrointestinal Stromal Tumors trials by city

Other conditions